글로벌 위장관 기질 종양 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

위장관 기질종양 시장 분석

위장관 기질 종양(GIST) 시장은 진단 및 치료 옵션의 발전에 힘입어 주목할 만한 성장을 경험하고 있습니다. 위장관의 카할 간질 세포에서 발생하는 희귀 종양인 GIST는 인지도가 높아지고 탐지 방법이 개선되어 조기 진단과 더 나은 환자 결과가 가능해졌습니다. 표적 치료의 최근 발전, 특히 새로운 티로신 키나제 억제제의 승인은 GIST 환자의 치료 환경을 변화시켰습니다. 예를 들어, 이마티닙 및 수니티닙과 같은 약물의 도입은 진행성 GIST로 진단받은 개인의 생존율과 삶의 질을 크게 개선했습니다. 게다가 차세대 치료법과 복합 치료법에 대한 지속적인 연구가 치료 효능을 더욱 향상시킬 것으로 예상됩니다. 또한 개인 맞춤 의학에 초점을 맞춘 임상 시험의 증가는 유전자 프로파일링을 기반으로 한 맞춤형 치료법의 잠재력을 강조하여 혁신적인 치료 접근 방식의 길을 열었습니다. GIST 시장이 계속 발전함에 따라 다학제 치료와 환자 중심 전략에 대한 강조가 점점 더 두드러지고 있으며, 이는 이 어려운 진단을 받는 환자에게 더 밝은 미래를 약속합니다.

위장관 기질종양 시장 규모

글로벌 위장관 기질 종양 시장 규모는 2023년에 12억 1,000만 달러로 평가되었으며, 2031년까지 20억 2,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.60%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

위장관 기질 종양 시장 동향

“ 개인화 의학의 채택 증가”

위장관 기질 종양(GIST) 시장은 표적 치료의 발전과 희귀 종양에 대한 인식 증가로 인해 주목할 만한 성장을 경험하고 있습니다. 이 시장의 주요 추세는 개인 유전적 프로필에 따라 치료를 맞춤화하는 개인화 의학의 채택이 증가하고 있다는 것입니다. 예를 들어, QINLOCK(리프레티닙)과 같은 약물의 승인은 여러 이전 치료에 반응하지 않은 진행성 GIST 환자의 치료 옵션을 혁신했습니다. 이러한 표적 치료는 광범위한 KIT 및 PDGFRα 돌연변이를 특별히 다루어 이전에는 표준 치료에만 국한되었던 환자에게 효과적인 관리를 제공합니다. 또한, 검사에서 바이오마커 에 대한 강조가 커지면서 개인이 특정 종양 프로필에 가장 적합한 치료를 받도록 하여 환자 결과가 향상되고 있습니다. 의료 서비스 제공자가 이러한 고급 치료 방식을 활용하는 데 더 능숙해짐에 따라 GIST 시장은 상당한 확장을 앞두고 있으며 이 어려운 상태와 싸우는 환자에게 새로운 희망을 제공합니다.

보고서 범위 및 위장관 기질 종양 시장 세분화         

Gastrointestinal Stromal Tumor Market Definition

Gastrointestinal stromal tumor (GIST) is a type of tumor that originates in the gastrointestinal tract, most commonly in the stomach or small intestine. These tumors arise from interstitial cells of Cajal or precursor cells, which are part of the autonomic nervous system and help regulate gut motility. GISTs are characterized by the presence of specific genetic mutations, often in the KIT or PDGFRA genes, which drive their growth. GISTs are distinct from other gastrointestinal tumors due to their unique histological features and specific treatment options, primarily targeted therapies that inhibit the signaling pathways associated with the mutations.

Gastrointestinal Stromal Tumor Market Dynamics

Drivers

• Increasing Incidence of Gastrointestinal Stromal Tumor

The increasing incidence of gastrointestinal stromal tumors (GISTs) is a crucial driver for market growth, reflecting a significant rise in diagnoses over the years. According to recent studies, GISTs account for approximately 1-3% of all gastrointestinal tumors, with an estimated incidence of 10-20 cases per million people annually. This rising prevalence is largely attributed to enhanced awareness among healthcare providers and patients about GISTs and their symptoms, leading to more frequent diagnostic testing and earlier detection. As a result, the demand for effective treatment options, including targeted therapies like imatinib and sunitinib, is expected to grow significantly. Such growing recognition of GISTs as a distinct clinical entity underscores the importance of advancing treatment options, ultimately driving the gastrointestinal stromal tumor market forward.

• Growing Investment in Research and Development (R&D)

The growing investment in research and development (R&D) for gastrointestinal stromal tumor (GIST) treatments is significantly propelling market expansion. Pharmaceutical companies are increasingly allocating funds towards R&D initiatives, with an estimated global spending of around USD 145 billion in 2022, reflecting a trend toward discovering novel therapies and enhancing existing treatment modalities. Ongoing clinical trials, such as those investigating the efficacy of new targeted therapies and combination treatments, are critical in this effort; for instance, recent studies are exploring the potential of innovative agents such as Ripretinib and Avapritinib, which have shown promise in advanced GIST cases. These investments aim to secure new drug approvals and strive to expand the therapeutic landscape, ultimately leading to improved patient outcomes and prognoses. As a result, the commitment of pharmaceutical companies to advancing GIST treatment options is a key driver in the gastrointestinal stromal tumor market, fostering an environment ripe for innovation and progress in patient care.

Opportunities

• Rise in Emergence of Targeted Therapies

Emerging targeted therapies are significantly transforming the treatment landscape for gastrointestinal stromal tumor (GIST) patients, offering new hope for those who have not responded to existing treatments. Drugs like QINLOCK (Ripretinib) and Avapritinib specifically target genetic mutations, such as KIT and PDGFRA, that drive GIST growth. For instance, QINLOCK is particularly effective for patients who have undergone multiple prior therapies, providing a much-needed option for those with advanced disease. Such shift towards precision medicine enhances the effectiveness of treatment and reduces the likelihood of side effects associated with broader therapeutic approaches. The continued development and approval of such targeted therapies are poised to expand market opportunities, as they improve patient outcomes and increase demand for specialized GIST treatments.

• Increasing Awareness and Diagnosis of GIST

Increased awareness and diagnosis of gastrointestinal stromal tumors (GIST) among healthcare professionals and the general public are critical market opportunities that can lead to earlier detection and improved patient outcomes. As educational initiatives and advocacy efforts highlight the signs and symptoms of GIST, more patients are likely to seek medical attention sooner, facilitating timely interventions. For instance, awareness campaigns led by organizations such as the GIST Support International have empowered both patients and doctors to recognize the symptoms of GIST, which can often be mistaken for other gastrointestinal issues. Early diagnosis can significantly enhance treatment options, including access to targeted therapies that are more effective in the earlier stages of the disease. Consequently, this increase in awareness leads to better patient outcomes and expands the potential market for GIST treatments as more individuals are identified and treated for this rare tumor type.

Restraints/Challenges

• Limited Patient Population

The limited patient population for gastrointestinal stromal tumors (GISTs) presents a significant challenge for the market, as these tumors are classified as rare conditions. This rarity results in a smaller market size, which can deter pharmaceutical companies from investing in research and development for new therapies. For instance, GISTs account for only about 1% of all gastrointestinal tumors, leading to fewer patients participating in clinical trials and a reduced incentive for companies to pursue innovative treatments. This lack of investment can stall the development of potentially life-saving medications, leaving patients with limited options. Consequently, the challenge posed by a limited patient population hampers market growth and restricts access to new and effective therapies for those affected by GIST.

• Significant Expenses Related to Gastrointestinal Stromal Tumor Treatment

High treatment costs pose a significant challenge in the gastrointestinal stromal tumor (GIST) market, particularly for patients who lack adequate insurance coverage. Targeted therapies, such as QINLOCK (Ripretinib) and Avapritinib, while effective, can be prohibitively expensive, often costing thousands of dollars per month. For instance, patients without comprehensive health insurance may struggle to afford these medications, leading to delayed treatment or non-adherence, which can negatively impact their prognosis. This financial burden can deter patients from seeking timely interventions, exacerbating health disparities and leading to poorer health outcomes overall. Consequently, the high costs associated with GIST treatments significantly limit access to care and present a major challenge for the market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Gastrointestinal Stromal Tumor Market Scope

The market is segmented on the basis of treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Gastrointestinal Stromal Tumor Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, treatment type, route of administration, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the gastrointestinal stromal tumor (GIST) market, driven by a notable rise in the incidence of this rare cancer. The region's robust demand for targeted therapies reflects a growing preference for personalized treatment options, significantly improving patient outcomes. Additionally, the presence of advanced healthcare facilities equipped with cutting-edge technology further enhances treatment accessibility and effectiveness. This combination of factors positions North America as a dominant force in the GIST market, ensuring continued growth and innovation in therapeutic approaches.

Asia-Pacific region is poised for the highest market growth, fueled by a surge in awareness regarding gastrointestinal stromal tumors (GISTs) and their associated treatment options. As educational initiatives and healthcare campaigns spread, more individuals are recognizing the importance of early diagnosis and timely intervention. Additionally, the rapid rise in disposable income among the population is enabling greater access to advanced healthcare services and targeted therapies. This combination of heightened awareness and improved economic conditions positions Asia-Pacific as a significant player in the GIST market, driving demand for innovative treatment solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Gastrointestinal Stromal Tumor Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Gastrointestinal Stromal Tumor Market Leaders Operating in the Market Are:

• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Blueprint Medicines Corporation (U.S.)
• NATCO Pharma Limited (India)

Latest Developments in Gastrointestinal Stromal Tumor Market

• In August 2024, Kura Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to advancing precision medicines for cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Ziftomenib. This powerful and selective menin inhibitor is being developed for the treatment of advanced gastrointestinal stromal tumors (GIST)
• 2021년 9월, 혁신적인 상업 단계 바이오제약 회사인 Zai Lab은 대만 식품의약국이 이전에 이마티닙을 포함한 3개 이상의 키나제 억제제로 치료받은 성인 진행성 위장관 기질 종양(GIST) 환자를 치료하기 위한 QINLOCK(리프레티닙)에 대한 신약 신청(NDA)을 승인했다고 발표했습니다. QINLOCK은 GIST 진행과 관련된 광범위한 KIT 및 PDGFRα 돌연변이를 특별히 표적으로 삼습니다.
• 2020년 5월, 미국 식품의약국은 Qinlock(Ripretinib) 정제를 승인하여, 위장관에서 발생하는 종양인 진행성 위장관 기질 종양(GIST)에 대한 4차 치료제로 특별히 승인된 최초의 신약이 되었습니다. Qinlock은 이전에 Imatinib을 포함한 3가지 이상의 키나제 억제제 요법을 받은 성인 환자를 대상으로 합니다.

SKU-54246